VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 14, 2026

Stock Comparison

AbbVie Inc. vs Bio-Rad Laboratories, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$389B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

Bio-Rad Laboratories, Inc.

BIO · New York Stock Exchange

Market cap (USD)$8.7B
Gross margin (TTM)52.3%
Operating margin (TTM)8.8%
Net margin (TTM)-26.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2025-12-30
Moat score
61/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.

View BIO analysis

Comparison highlights

  • Moat score gap: AbbVie Inc. leads (65 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
  • Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics).
  • Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Bio-Rad Laboratories, Inc. has 6 across 3.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

Bio-Rad Laboratories, Inc.

Clinical Diagnostics

Market

In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls

Geography

Global

Customer

Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories

Role

IVD OEM / installed-base consumables supplier (systems + kits + controls)

Revenue share

59.9%

Side-by-side metrics

AbbVie Inc.
Bio-Rad Laboratories, Inc.
Ticker / Exchange
ABBV - New York Stock Exchange
BIO - New York Stock Exchange
Market cap (USD)
$389B
$8.7B
Gross margin (TTM)
n/a
52.3%
Operating margin (TTM)
n/a
8.8%
Net margin (TTM)
n/a
-26.4%
Sector
Healthcare
Healthcare
Industry
n/a
Medical - Devices
HQ country
US
US
Primary segment
Immunology
Clinical Diagnostics
Market structure
Oligopoly
Oligopoly
Market share
n/a
9%-11% (implied)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
61 / 100
Moat domains
Legal, Demand
Supply, Demand, Legal
Last update
2026-01-11
2025-12-30

Moat coverage

Shared moat types

No overlap yet.

AbbVie Inc. strengths

IP Choke PointRegulated Standards PipeBrand Trust

Bio-Rad Laboratories, Inc. strengths

Scope EconomiesDistribution ControlCapex Knowhow ScaleInstalled Base ConsumablesSwitching Costs GeneralCompliance Advantage

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

Bio-Rad Laboratories, Inc. segments

Full profile >

Life Science

Competitive

40.1%

Clinical Diagnostics

Oligopoly

59.9%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.